Description: Biotech spin-off of University of Cordoba (EBT-UCO) and IMIBIC. The R&D line focuses on predicting responders vs non-reponders to biologics, in patients suffering from rhuematic diseases. The aim of this project is to develop a test that will combine a blood analysis, clinical information and bioinformatics by developing a Diagnostic test that identifies the ‘non-responders’ before start of therapy. COBIOMIC is also the first core-lab of Olink (OLK – NASDAQ) providing high-throughput proteomic analysis (protein biomarkers) using qPCR on 1ul of any biological sample type. Boosting personalised medicine in various disease areas.